





Chief Guest Dr. Mary Teopista (Center), Amb. Francis Butagira, Registrar General Ms. Mercy K. Kainobwisho and URSB board members pose for a photo at the URSB ISO Certification External Stakeholders celebration
Hon. Nobert Mao congratulates the Registrar General, Ms. Mercy K. Kainobwisho, and Board member, Ms. Lydia A. Sekkabira on the ISO 9001:2015 certification milestone
Mr. Hamidu Tumuhimbise, a senior Registration Officer, attends to a client during the UEB claimants exercise at the Uganda Business Facilitation Center, Kololo
A delegation from PACRA led by the Deputy Registrar Mr. Chewe Peter Chilufya (Center) visited URSB for a 3 days benchmarking visit on the Intellectual Property Registry on how systems operate, the digital improvements implemented and how these reforms contribute to reduced turnaround time
A delegation from UNOC visits URSB to benchmark on the Digital Transformation Journey.
Director General WIPO Mr. Daren Tang, Minister of Justice Hon. Nobert Mao, The Registrar General Ms. Mercy K. Kainobwisho, URSB Board members a delegation from WIPO pause for a photo at the Uganda Business Facilitation Center during the DG’s mission to Uganda

URSB Partners with Dei Biopharma to Advance Innovation through Intellectual Property Protection
To foster scientific innovation and strengthen intellectual property (IP) protection, the Uganda Registration Services Bureau (URSB) conducted a working visit to Dei Biopharma last week, an emerging pharmaceutical facility in Matugga Town Council.
Led by former Commissioner for Intellectual Property, Mr. Gilbert Agaba, the URSB team held discussions with Dei Biopharma’s leadership to explore ways of protecting and strategically managing the company’s intellectual property assets.
The visit follows international recognition of Dei Biopharma’s recent patent application in the U.S. for the world’s first universal Foot and Mouth Disease (FMD) vaccine.
URSB used the engagement to better understand the scope of pharmaceutical research being undertaken by Dei Biopharma and to identify how national IP systems can support such innovations. The discussions also touched on opportunities for collaboration on international IP filings, positioning Uganda as a leader in bioscience and pharmaceutical research.

Led by Dr. Matthias Magoola, the facility is positioned as a strategic national investment aligned with the government’s science, technology, and innovation agenda. It aims to significantly decrease Uganda’s reliance on imported drugs, boost local pharmaceutical capacity, and make medicines more affordable across the region.
Dei Biopharma produces a diverse range of pharmaceuticals, including those for infectious diseases, cancer, and other chronic illnesses.
URSB commended Dei Biopharma for its scientific leadership and efforts in pharmaceutical development. The bureau pledged continued technical support to innovators across the country in safeguarding their creations.